Clinical trial recruitment for ABBV-744 study Fundamentals Explained
In Phase C, contributors will obtain ABBV-744 and oral navitoclax. In Section D, contributors will receive ABBV-744 and ruxolitinib. Members will acquire treatment until finally illness progression or maybe the participants are unable to tolerate the study drugs.- Participant eaten grapefruit or grapefruit merchandise within 3 times just before the